Regulatory Compliance Services and Loss Prevention Solutions for the Pharma Industry
Pharma Compliance Group (PCG) is a team of former Drug Enforcement Administration (DEA) Special Agents, Diversion Investigators, and private security professionals dedicated to supporting the pharmaceutical industry. We specialize in compliance consulting, regulatory guidance, and field services for DEA-registered entities. With deep expertise in conducting inspections, evaluations, and investigations, PCG helps clients develop and implement robust compliance management solutions. Our team is committed to ensuring pharmaceutical organizations maintain adherence to the Controlled Substances Act (CSA) while navigating the complexities of regulatory compliance.
Matt Murphy retired from the Drug Enforcement Administration (DEA) as the Assistant Special Agent in Charge (ASAC) in the New England Field Division after a twenty six year career. A regulatory subject matter expert with executive leadership experience Matt served as the Chief of Pharmaceutical Investigations for the DEA and was instrumental in developing and implementing DEA’s strategy to dismantle drug trafficking organizations illicitly distributing pharmaceutical controlled substances.
Upon retirement from the DEA Matt founded the Pharma Compliance Group (PCG), providing pharmaceutical compliance expertise to assist clients comply with the Controlled Substances Act (CSA), and the regulations contained in the Code of Federal Regulations (CFR), that pertain to pharmaceutical drug manufacturers, wholesale drug distributors, and pharmacy companies. Matt leads the company’s regulatory consulting operations to include on-site and off-site (audit) review services.
From 2017 until 2021 Matt served as the Chief Compliance Officer for Khiron Life Sciences, the first licensed vertically integrated medical cannabis company in the country of Colombia. Serving as Chief Compliance Officer, Matt established Khiron’s seed to sale compliance program implementing similar CSA/CFR mandates that DEA utilizes to regulate the US pharmaceutical industry.
Matt will provide guidance and expertise on regulatory matters pertaining to pharmaceutical controlled substance compliance and cannabis compliance for the Pharma Compliance Group and C1 Compliance Group.
Mimi Paredes is a strategic partner of the Pharma Compliance Group and a consulting expert on state and federal laws involving the diversion of pharmaceutical controlled substances. Mimi is the founder and CEO of 801 Consulting, a group of former U.S. Drug Enforcement Administration (DEA) officials, attorneys and policy advisors who are helping clients navigate the Controlled Substances Act and relevant regulations to develop strong internal policies and procedures. 801 Consulting specializes in comprehensive reviews of manufacturing, distribution, and dispensing systems and processes, analyzing and identifying problem areas, and recommending opportunities to implement proactive and corrective measures, with a focus on helping clients fulfill their legal obligations.
Prior to founding 801 Consulting, Mimi worked at the U.S. Food and Drug Administration Center for Tobacco Products as a senior regulatory counsel responsible for oversight of the civil money penalty and no-tobacco-sale order processes involving tobacco product retailers. She also spent nearly fifteen years at the DEA in several roles, including litigation attorney and principal policy advisor to the Deputy Assistant Administrator on issues related to the diversion of controlled substances and listed chemicals into illegitimate channels. In this role, Mimi oversaw the execution of various legislative, programmatic, and investigative/regulatory initiatives. She also managed a team of attorneys, scientists, and investigators throughout the regulation drafting process, including policy development and implementation.
Mimi is a former U.S. Air Force reservist and began her legal career as an active duty commissioned officer in the U.S. Navy Judge Advocate General’s Corps. She earned her law degree from the George Washington University National Law Center and her undergraduate degree from the University of California, Berkeley. Mimi currently resides in the Washington, D.C. area.
Currently Bill holds the position of subject matter expert with Pharma Compliance Group providing comprehensive compliance assessments for pharmaceutical customers focusing on controlled substance distribution, order monitoring systems, dispensing data analysis and overall risk mitigation strategies emphasizing the corresponding responsibility and know your customer edicts of federal regulation.
Bill is a retired law enforcement professional with twenty years of service which was primarily focused on pharmaceutical diversion investigations resulting in both state and federal prosecutions.
Subsequent to retirement from law enforcement in 2007, Bill has held positions throughout the pharmaceutical industry to include: internal retail pharmacy investigations and audits for a national pharmacy chain, federal contractor responsible for Medicare Part D fraud investigations involving pharmacies, physicians and beneficiaries and managing corporate compliance investigations and customer due diligence programs for a national pharmaceutical distributor.
Bill held the position of Education and Training Director as a member of the national board of directors for the National Association of Drug Diversion Investigators (NADDI) from 2006 to 2010. Bill developed several training modules related to pharmaceutical drug fraud, theft and abuse which he has provided to law enforcement, regulatory and health care professionals throughout the United States. Bill has participated as a subject matter expert in several media interviews and panel discussions regarding prescription drug diversion.
His varied background within the pharmaceutical industry has provided Bill the opportunity to collaborate in the development of various controlled substance compliance programs designed to proactively identify risk potential as it relates to the national distribution and dispensing of controlled substances.
Bill’s prior law enforcement career coupled with his exposure to the commercial pharmaceutical industry provides valuable insight to the diversion of controlled substances throughout the supply chain and in the development of risk mitigation strategies for our clients.
Chris is a strategic partner of the Pharma Compliance Group and a consulting expert regarding the state and federal laws involving controlled substances. Chris recently retired from the Drug Enforcement Administration after a thirty-two-year career as a DEA Diversion Investigator. He served as a field investigator in Dallas, TX, Cleveland, OH, and Baltimore, MD, conducting complex regulatory investigations involving the controlled substance handling procedures of drug manufacturers, distributors, narcotic treatment programs and retail pharmacies.
Chris was assigned to the office of Pharmaceutical Investigations at DEA headquarters, providing guidance and assistance to field units relative to administrative, civil, and or criminal investigations. He also provided written guidance to registrants seeking interpretation of DEA policies and regulations. Chris received the DEA Administrators Award for his leadership in a DEA operation that dismantled ten illegal internet pharmacies responsible for illegally distributing millions of dosage units of controlled substances across the United States.
Chris served sixteen years in various DEA management positions and retired in May 2022 as a Supervisory Diversion Investigator in Detroit, Michigan.
